Cardiol Therapeutics (CRDL) Corporate Presentation summary

Strategic focus and pipeline

• Advancing therapies targeting inflammation in the heart, with late-stage programs for recurrent pericarditis, acute myocarditis, and heart failure.

• Lead candidate CardiolRx™ targets inflammasome activation, offering a non-immune suppressing, potentially disease-modifying therapy.

• Strong Phase II data in pericarditis (MAVERIC) and myocarditis (ARCHER) support further development.

• IND-enabling program for CRD-38 in heart failure, targeting a multi-billion-dollar market.

Clinical trial highlights

• MAVERIC Phase II showed rapid, durable pain reduction and inflammation control in recurrent pericarditis, with 71% recurrence-free during extension.

• ARCHER Phase II in acute myocarditis demonstrated significant reductions in LV mass and trends toward reduced fibrosis and edema, with safety confirmed.

• Phase III MAVERIC trial is enrolling high-risk pericarditis patients, aiming for 50% enrollment in H2 2025 and completion in H1 2026.

Market opportunity and differentiation

• CardiolRx™ addresses large, underserved populations: 38,000 recurrent pericarditis and 46,000 acute myocarditis patients in the U.S.

• Orphan Drug Designation granted for pericarditis; potential for additional designations in myocarditis.

• Recurrent pericarditis market expected to exceed $1B by 2028, with CardiolRx™ offering a differentiated, accessible, non-immunosuppressive profile.